Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

NCT: NCT07541404 · NOT_YET_RECRUITING

NCT IDNCT07541404
StatusNOT_YET_RECRUITING
Start Date2026-07
Completion2028-04

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the NeoCast Embolic System for treatment of symptomatic subacute or chronic subdural hematoma (SDH) adjunctive to surgery.

Frequently Asked Questions

What is MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma?

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma is a clinical trial registered under NCT07541404. Current status: NOT_YET_RECRUITING.

What is the status of NCT07541404?

The current status of NCT07541404 (MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma) is: NOT_YET_RECRUITING.

When did MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma start?

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma started on 2026-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑